Supplementary Table 4 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Year: 2023
Type: supplementary-materials
Abstract: Refametinib geometric mean (% coefficient of variation) single-dose pharmacokinetic data on day 1 of course 1
Authors: Alex A. Adjei, Donald A. Richards, Anthony El-Khoueiry, Fadi Braiteh, Carlos H.R. Becerra, Joe J. Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, Diane P. Leffingwell, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li-Tain Yeh, Sonny Gunawan, David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J. Clendeninn
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362397430